Shenzhen Hepalink announced a US$69 million investment into Canada’s Resverlogix via a private placement that will raise Hepalink’s stake in Resverlogix to 45%. Resverlogix is currently conducting a Phase III trial of apabetalone (RVX-208), a first-in-class, small molecule BET (bromodomain and extra-terminal) inhibitor. Resverlogix expects RVX-208 to raise a patient’s high-density cholesterol.
Source: ChinaBio Today
